Anita Seto

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignee: Miragen Therapeutics, Inc.. Active years: 2015-2019.

USPTO Granted Patents = 7 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Boulder, CO (US) (2015 - 2019)
Golden, CO (US) (2017 - 2019)

Company Filing History:

7 out of 20

Miragen Therapeutics, Inc.

patents

Years Active: 2015-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10316318 - Oligonucleotide compositions and uses thereof (2019-06-11),

2. 10280422 - MiR-92 inhibitors and uses thereof (2019-05-07),

3. 9994852 - Oligonucleotide compositions and uses thereof (2018-06-12),

4. 9885042 - miR-92 inhibitors and uses thereof (2018-02-06),

5. 9771585 - miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) (2017-09-26),

6. 9752143 - Locked nucleic acid inhibitor of miR-145 and uses thereof (2017-09-05),

7. 9163235 - Inhibitors of the miR-15 family of micro-RNAs (2015-10-20),

Title: Anita Seto: Innovator in Oligonucleotide Therapeutics

Introduction

Anita Seto is a prominent inventor based in Boulder, Colorado, known for her significant contributions to the field of oligonucleotide therapeutics. With a total of seven patents to her name, she has made remarkable strides in developing innovative treatments for various medical conditions, particularly cancer.

Latest Patents

Among her latest patents, one notable invention is focused on oligonucleotide compositions that inhibit miR-155. This invention provides methods for treating cancers, such as T cell lymphoma, by administering oligonucleotide inhibitors of miR-155. Additionally, it outlines methods for reducing or inhibiting the proliferation of malignant T cells. Another significant patent involves miR-92 inhibitors, which offer methods for inhibiting the function and activity of miR-92 in subjects. This invention also includes methods for evaluating the efficacy of therapeutics aimed at promoting wound healing.

Career Highlights

Anita Seto is currently associated with Miragen Therapeutics, Inc., where she continues to advance her research and development efforts in the field of oligonucleotide therapies. Her work has been instrumental in paving the way for new treatment options that target specific molecular pathways involved in cancer and other diseases.

Collaborations

Anita collaborates with talented professionals in her field, including Christina Marie Dalby and Aimee Jackson. These collaborations enhance her research and contribute to the innovative solutions being developed at Miragen Therapeutics.

Conclusion

Anita Seto's contributions to the field of oligonucleotide therapeutics exemplify her dedication to advancing medical science. Her innovative patents and collaborative efforts position her as a key figure in the ongoing fight against cancer and other serious health conditions.